Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01238796 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin
A Phase 1 study of End Stage Renal Disease and Kidney Diseases, sponsored by Cumberland Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 4
- Study locations
NCT01238796 is a Phase 1 study of End Stage Renal Disease and Kidney Diseases that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 45 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT01238796, a Phase 1 study of End Stage Renal Disease and Kidney Diseases, has completed, sponsored by Cumberland Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate the effect of renal function on the biological activity of telavancin using blood samples obtained from subjects with normal renal function, severe renal impairment, and end stage renal disease.
Conditions Studied
Interventions
- DRUG telavancin
Study Locations (4)
Florida
- Clinical Pharmacology of Miami - Miami
- Orlando Clinical Research Center - Orlando
Minnesota
- DaVita Clinical Research - Minneapolis
Tennessee
- New Orleans Center for Clinical Research - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2010-12 |
| Est. Completion | 2011-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01238796
The ClinicalTrials.gov registry entry for NCT01238796 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (95% lower). The listed sponsor is Cumberland Pharmaceuticals, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which telavancin is the first listed.
NCT01238796 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Florida, Minnesota, Tennessee.
Frequently Asked Questions
What is clinical trial NCT01238796 about?
NCT01238796 is a clinical study titled "A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin". The purpose of this study is to evaluate the effect of renal function on the biological activity of telavancin using blood samples obtained from subjects with normal renal function, severe renal impairment, and end stage renal disease.
What is the current status of trial NCT01238796?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2010-12. Estimated completion is 2011-02.
What conditions does trial NCT01238796 study?
This clinical trial studies the following conditions: End Stage Renal Disease, Kidney Diseases.
What interventions are being tested in trial NCT01238796?
The interventions under investigation include: telavancin (DRUG).
Who is sponsoring clinical trial NCT01238796?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01238796 being conducted?
This trial has 4 study locations across Florida, Minnesota, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses
RECRUITING · Phase 1
-
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
RECRUITING · Phase 1
-
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
ACTIVE NOT RECRUITING · Phase 1
-
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
COMPLETED · Phase 1
-
Plazomicin Study in ESRD Patients Receiving IHD
COMPLETED · Phase 1
-
Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.